Aerovate Therapeutics Net Current Debt 2020-2024 | JBIO
Aerovate Therapeutics net current debt from 2020 to 2024. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
Aerovate Therapeutics Annual Net Current Debt
(Millions of US $) |
| 2024 |
$N/A |
| 2023 |
$N/A |
| 2022 |
$N/A |
| 2021 |
$N/A |
| 2020 |
$N/A |
| 2019 |
$N/A |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.008B |
$0.000B |
|
Aerovate Therapeutics Inc. is a clinical stage biopharmaceutical company. It focused on developing drugs for cardiopulmonary disease. The company's product pipeline consist AV-101. Aerovate Therapeutics Inc. is based in BOSTON.
|
